title: The effect of Ginkgo biloba on the activity of catalase and lipid peroxidation in experimental strangulation ileus.
abstract: This study was designed to assess the therapeutic effect of Ginkgo biloba extract (EGb 761) in experimental strangulation ileus. Rats were divided into control (n = 7), placebo (n = 11), and EGb-treated (n = 11) groups. No surgical procedure was carried out on the control group. Strangulation ileus was produced in the placebo and EGb groups for 2.5 h. At the end of this period, 100 mg/kg EGb in 1 ml of saline was injected intraperitoneally to the EGb-treated group. In the placebo group, animals received an equivalent amount of saline intraperitoneally; 24 h later, repeat laparotomies were performed to take blood and intestinal tissue samples. The EGb treatment decreased tissue malondialdehyde levels and increased catalase activities compared with the placebo group (P < 0.05 for both). Serum creatine kinase and phosphorus levels were also determined in all groups. In the placebo group these were significantly higher than in the control group (P < 0.01 and P < 0.05, respectively). In the EGb group these were not different from controls and the increase in creatine kinase activity in the EGb group was not as high as in the placebo group (P < 0.05). Our results suggest that EGb could be preventive against the effects of strangulation ileus in a rat model.
authors.affiliation: Department of Biochemistry, Osmangazi University, Faculty of Medicine, Eskişehir, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Colak
authors.forename: A
authors.initials: A
authors.lastname: Sahin
authors.forename: O
authors.initials: O
authors.lastname: Alataş
authors.forename: M
authors.initials: M
authors.lastname: Inal
authors.forename: B
authors.initials: B
authors.lastname: Yaşar
authors.forename: H
authors.initials: H
authors.lastname: Kiper
mesh_terms: D000818:Animals; D002374:Catalase / Q000032:analysis*; D003402:Creatine Kinase / Q000032:analysis; D005419:Flavonoids / Q000627:therapeutic use*; D020441:Ginkgo biloba; D007077:Ileal Diseases / Q000150:complications / Q000188:drug therapy*; D007082:Ileum / Q000098:blood supply* / Q000737:chemistry; D007415:Intestinal Obstruction / Q000150:complications / Q000188:drug therapy*; D007511:Ischemia / Q000188:drug therapy*; D008026:Ligation; D015227:Lipid Peroxidation; D008315:Malondialdehyde / Q000032:analysis*; D010084:Oxidation-Reduction; D010710:Phosphates / Q000032:analysis; D010936:Plant Extracts / Q000627:therapeutic use*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D051381:Rats; D015427:Reperfusion Injury / Q000517:prevention & control*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D000096983:Ginkgo Extract
chemical_list: D002374:Catalase; D003402:Creatine Kinase; D005419:Flavonoids; D008315:Malondialdehyde; D010710:Phosphates; D010936:Plant Extracts; D010972:Platelet Activating Factor; D014665:Vasodilator Agents; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract